Skip to main
ANAB

AnaptysBio (ANAB) Stock Forecast & Price Target

AnaptysBio (ANAB) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

AnaptysBio Inc. demonstrates a strong financial outlook due to the successful settlement with GSK, which significantly increased royalty rates on Jemperli sales and provided a substantial one-time payment of $60 million, enhancing the company's liquidity. The ongoing clinical development of promising antibody candidates, including rosnilimab and ANB032, positions AnaptysBio to address substantial unmet medical needs in inflammation and immuno-oncology, offering potential for substantial revenue growth. Furthermore, management's confidence in navigating the legal landscape with GSK suggests that the company maintains a viable financial buffer to support its operations and clinical programs, reinforcing a positive outlook for future performance.

Bears say

AnaptysBio Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety issues with its clinical or preclinical programs and the possibility of lower-than-expected efficacy in ongoing trials. Increased commercial competition and regulatory concerns regarding the company's assets further complicate its position, threatening to hinder approval and market performance of key products such as rosnilimab and Jemperli. Additionally, unfavorable legal outcomes could adversely impact revenues and legal costs, exacerbating financial instability for the company.

AnaptysBio (ANAB) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AnaptysBio (ANAB) Forecast

Analysts have given AnaptysBio (ANAB) a Buy based on their latest research and market trends.

According to 9 analysts, AnaptysBio (ANAB) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AnaptysBio (ANAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.